1887

Journal of General Virology header logo

Volume 104, Issue 5

Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ.1.1 and XBB.1 Open Access

Abstract

Recent 2022 SARS-CoV-2 Omicron variants, have acquired resistance to most neutralizing anti-Spike monoclonal antibodies authorized, and the BQ.1.* sublineages are notably resistant to all authorized monoclonal antibodies. Polyclonal antibodies from individuals both vaccinated and recently recovered from Omicron COVID-19 (VaxCCP) could retain new Omicron neutralizing activity. Here we reviewed BQ.1.* virus neutralization data from 920 individual patient samples from 43 separate cohorts defined by boosted vaccinations (Vax) with or without recent Omicron COVID-19, as well as infection without vaccination (CCP) to determine level of BQ.1.* neutralizing antibodies and percent of plasma samples with neutralizing activity. More than 90 % of the plasma samples from individuals in the recently (within 6 months) boosted VaxCCP study cohorts neutralized BQ.1.1, and BF.7 with 100 % neutralization of WA-1, BA.4/5, BA.4.6 and BA.2.75. The geometric mean of the geometric mean 50 % neutralizing titres (GM (GMT) were 314, 78 and 204 for BQ.1.1, XBB.1 and BF.7, respectively. Compared to VaxCCP, plasma sampled from COVID-19 naïve subjects who also recently (within 6 months) received at least a third vaccine dose had about half of the GM (GMT) for all viral variants. Boosted VaxCCP characterized by either recent vaccine dose or infection event within 6 months represents a robust, variant-resilient, neutralizing antibody source against the new Omicron BQ.1.1, XBB.1 and BF.7 variants.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): BF.7: virus neutralization , BQ.1.1 , convalescent plasma , COVID-19 , SARS-CoV-2 and XBB
Funding
This study was supported by the:
  • National Center for Advancing Translational Sciences (Award UL1TR003098)
    • Principle Award Recipient: ApplicableNot
  • National Center for Advancing Translational Sciences (Award U24TR001609-S3)
    • Principle Award Recipient: ApplicableNot
  • National Institute of Allergy and Infectious Diseases (Award 3R01AI152078-01S1)
    • Principle Award Recipient: CasadevallArturo
  • State of Maryland
    • Principle Award Recipient: J SullivanDavid
  • Bloomberg Family Foundation
    • Principle Award Recipient: J SullivanDavid
  • U.S. Department of Defense (Award W911QY2090012)
    • Principle Award Recipient: J SullivanDavid
© 2023 The Authors
  • This is an open-access article distributed under the terms of the Creative Commons Attribution License. This article was made open access via a Publish and Read agreement between the Microbiology Society and the corresponding author’s institution.
Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.001854
2023-05-11
2024-05-08
Loading full text...

Full text loading...

/deliver/fulltext/jgv/104/5/jgv001854.html?itemId=/content/journal/jgv/10.1099/jgv.0.001854&mimeType=html&fmt=ahah

References

  1. Senefeld JW, Franchini M, Mengoli C, Cruciani M, Zani M et al. COVID-19 convalescent plasma for the treatment of immunocompromised patients: a systematic review and meta-analysis. JAMA Netw Open 2023; 6e2250647 [View Article] [PubMed]
     [Google Scholar]
  2. Arora P, Kempf A, Nehlmeier I, Schulz SR, Jäck H-M et al. Omicron sublineage BQ.1.1 resistance to monoclonal antibodies. Lancet Infect Dis 2023; 23:22–23 [View Article] [PubMed]
     [Google Scholar]
  3. Cao Y, Jian F, Wang J, Yu Y, Song W et al. Imprinted SARS-Cov-2 humoral immunity induces CONVERGENT Omicron RBD evolution. bioRxiv 2022 [View Article]
     [Google Scholar]
  4. Sullivan DJ, Franchini M, Joyner MJ, Casadevall A, Focosi D. Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources. Nat Commun 2022; 13:6478 [View Article] [PubMed]
     [Google Scholar]
  5. Li M, Beck EJ, Laeyendecker O, Eby Y, Tobian AAR et al. Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern. Blood Adv 2022; 6:3678–3683 [View Article]
     [Google Scholar]
  6. Wang Z, Muecksch F, Schaefer-Babajew D, Finkin S, Viant C et al. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature 2021; 595:426–431 [View Article]
     [Google Scholar]
  7. Shrock E, Fujimura E, Kula T, Timms RT, Lee I-H et al. Viral EPITOPE profiling of COVID-19 patients reveals cross-reactivity and correlates of severity. Science 2020; 370:eabd4250 [View Article] [PubMed]
     [Google Scholar]
  8. Hinton DM. Convalescent Plasma EUA Letter of Authorization 06032021. In: FDA, editor. FDA in brief. FDA; 2021 https://www.fda.gov/media/141477/download
  9. O’Shaughnessy JA. Convalescent plasma EUA letter of authorization 12282021. FDA Website. n.d https://public4.pagefreezer.com/browse/FDA/09-05-2023T13:58/https://www.fda.gov/media/141477/download
  10. Qu P, Evans JP, Faraone J, Zheng Y-M, Carlin C et al. Distinct neutralizing antibody escape of SARS-Cov-2 Omicron Subvariants BQ.1, BQ.1.1, BA.4.6, BF.7 and BA.2.75.2. bioRxiv2022.10.19.512891 2022 [View Article] [PubMed]
     [Google Scholar]
  11. Davis-Gardner ME, Lai L, Wali B, Samaha H, Solis D. mRNA Bivalent booster enhances neutralization against BA.2.75.2 and BQ.1.1. bioRxiv [View Article]
     [Google Scholar]
  12. Wang Q, Iketani S, Li Z, Liu L, Guo Y et al. Alarming antibody evasion properties of rising SARS-Cov-2 BQ and XBB Subvariants. Cell 2023; 186:279–286 [View Article] [PubMed]
     [Google Scholar]
  13. Miller J, Hachmann NP, Collier AY, Lasrado N, Mazurek CR et al. Substantial neutralization escape by SARS-CoV-2 Omicron variants BQ.1.1 and XBB.1. N Engl J Med 2023; 388:662–664 [View Article]
     [Google Scholar]
  14. Planas D, Bruel T, Staropoli I, Guivel-Benhassine F, Porrot F et al. Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies. Nat Commun 2023; 14:824 [View Article] [PubMed]
     [Google Scholar]
  15. Zou J, Kurhade C, Patel S, Kitchin N, Tompkins K et al. Improved neutralization of Omicron BA.4/5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with bivalent BA.4/5 vaccine. N Engl J Med 2023; 388:854–857 [View Article]
     [Google Scholar]
  16. Kurhade C, Zou J, Xia H, Liu M, Chang HC et al. Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by 4 doses of parental mRNA vaccine or a BA.5-bivalent booster. Nat Med 2023; 29344–347 [View Article]
     [Google Scholar]
  17. Ito J, Suzuki R, Uriu K, Itakura Y, Zahradnik J et al. Convergent evolution of the SARS-CoV-2 Omicron subvariants leading to the emergence of BQ.1.1 variant. bioRxiv [View Article]
     [Google Scholar]
  18. Akerman A, Milogiannakis V, Jean T, Esneu C, Silva MR et al. Emergence and antibody evasion of BQ and BA.2.75 SARS-CoV-2 sublineages in the face of maturing antibody breadth at the population level. EBioMedicine 2023; 90:104545 [View Article]
     [Google Scholar]
  19. Sullivan DJ, Gebo KA, Shoham S, Bloch EM, Lau B et al. Early outpatient treatment for Covid-19 with convalescent plasma. N Engl J Med 2022; 386:1700–1711 [View Article] [PubMed]
     [Google Scholar]
  20. Villa C. OBRR EUA 26382 COVID-19 Convalescent Plasma. In: OBRR, editor. FDA; 2021 https://www.fda.gov/media/155159/download
  21. Levine AC, Fukuta Y, Huaman MA, Ou J, Meisenberg BR et al. COVID-19 convalescent plasma outpatient therapy to prevent outpatient hospitalization: a meta-analysis of individual participant data from five randomized trials. Clin Infect Dis 2023ciad088 [View Article] [PubMed]
     [Google Scholar]
  22. Stone M, Grebe E, Sulaeman H, Di Germanio C, Dave H et al. Evaluation of commercially available high-throughput SARS-CoV-2 serologic assays for serosurveillance and related applications. Emerg Infect Dis 2022; 28:672–683 [View Article] [PubMed]
     [Google Scholar]
  23. Patel EU, Bloch EM, Clarke W, Hsieh Y-H, Boon D et al. Comparative performance of five commercially available serologic assays to detect antibodies to SARS-CoV-2 and identify individuals with high neutralizing titers. J Clin Microbiol 2021; 59:e02257-20 [View Article] [PubMed]
     [Google Scholar]
  24. Zhang S, Ma P, Orzechowski M, Lemmer A, Rzasa K. High-throughput neutralization and serology assays reveal correlated but highly variable humoral immune responses in a large population of individuals infected with SARS-CoV-2 in the US between March and August 2020. mBio 2020 [View Article]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.001854
Loading
Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ.1.1 and XBB.1
J. Gen. Virol. 104, 001854 (2023); https://doi.org/10.1099/jgv.0.001854
/content/journal/jgv/10.1099/jgv.0.001854
/content/journal/jgv/10.1099/jgv.0.001854
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error